Your session is about to expire
← Back to Search
Kinase Inhibitor
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
Phase 2
Waitlist Available
Led By Patricia LoRusso, D.O.
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group
Summary
This phase II trial studies how well molecularly targeted therapy works in treating patients with melanoma that has spread to other parts of the body. Patients must have received or do not qualify for prior immunotherapy. Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. Molecularly targeted therapy works by treating patients with substances that kill cancer cells by targeting key molecules involved in cancer cell growth.
Eligible Conditions
- Melanoma
- Skin Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Best Overall Response Rate (BORR)
Secondary study objectives
Progression-Free Survival (PFS)
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Arm I (molecularly targeted therapy)Experimental Treatment5 Interventions
Patients undergo collection of tissue and blood samples for DNA and RNA analysis via sequencing. Based on the results of the DNA and RNA analysis, patients receive molecularly targeted therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
therapeutic procedure
2016
Completed Phase 2
~80
Binimetinib
FDA approved
Find a Location
Who is running the clinical trial?
Yale UniversityLead Sponsor
1,930 Previous Clinical Trials
3,033,425 Total Patients Enrolled
15 Trials studying Melanoma
727 Patients Enrolled for Melanoma
National Cancer Institute (NCI)NIH
13,958 Previous Clinical Trials
41,112,531 Total Patients Enrolled
564 Trials studying Melanoma
191,221 Patients Enrolled for Melanoma
Patricia LoRusso, D.O.Principal InvestigatorYale University